Statin therapy for people with compensated cirrhosis
Official title: Statin Therapy for patients with compensated Cirrhosis
Funded at University of Michigan at Ann Arbor · NIH-11591518 · Data updated 2026-11-12
A big, long-term study at a major university is looking at whether statins can help people with compensated cirrhosis live longer and feel better.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | September 22, 2021 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $610,662 |
| NIH project number | 5U01DK130113-06 |
| Project ID | NIH-11591518 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with compensated cirrhosis who are receiving care at participating hepatology clinics.
✕Less likely to help
Patients without access to statins or those with contraindications may not benefit.
What this research studies
This project will enroll a large group of patients with compensated cirrhosis from the University of Michigan to follow them over time. Researchers will collect clinical data and patient-reported outcomes to improve risk prediction for serious liver-related events. They will explore whether statin use is linked to fewer complications like hepatic decompensation or liver cancer and better quality of life. The study is organized as a multicenter effort to gather robust, real-world information that could guide future care.
Why it matters
Potential benefit: If successful, it could lead to safer, more effective use of statins in cirrhosis and better tools to predict who is at risk for complications.
How similar studies have gone: Preliminary observational data suggest potential benefits of statins in cirrhosis, but prospective data are needed.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Tapper, Elliot — University of Michigan at Ann Arbor
- Study coordinator: Tapper, Elliot
Related research
Other NIH-funded projects on the same topics.
-
Liver Cirrhosis Network: Centers for Clinical Research
A multicenter study in people with cirrhosis from different causes (including HIV, NASH, and alcohol-related liver disease) to collect data and samples and test new ways to predict and monitor disease progression.
-
Outcomes in cirrhosis from different causes and the role of HIV and simvastatin
This study looks at how cirrhosis from alcohol, HIV, and other causes affects patients and whether simvastatin can influence outcomes.
-
Liver Cirrhosis Network: Mayo Clinic's Clinical Research Center
A Mayo Clinic-led project will follow and help people with compensated cirrhosis, using data, imaging, and a big AI tool to predict when complications may happen and test whether a statin can improve outcomes.
-
Understanding how risk factors affect progression of cirrhosis and response to statins in patients with cirrhosis
This project follows people with cirrhosis to see what factors speed up their liver disease and whether statin medicines help prevent worsening.
-
Cirrhosis Network study to understand mortality and therapies
A large, multi-center study in people with cirrhosis to find better ways to predict deaths and test the potential of statins to prevent complications like liver cancer and liver failure.
-
Liver Cirrhosis Network: Longitudinal and Clinical Trial Studies
A network-wide NIH study focused on understanding cirrhosis better to prevent complications and improve care for people with advanced liver disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.